검색어: 0,74 (폴란드어 - 영어)

0, 74
0.74

- 74, 0
-74.0

74
74

- 0, 74
-0.74

↑ 74%
↑ 74%

74/ 74
72/ 72

(0, 52; 0, 74)
(0.59, 0.73)

5 lat 0, 74
5

0, 19 (- 0, 84, 0, 74)
(-0.31, 0.66)

0, 65%, 1, 74%).
0.65%, 1.74%).

0, 58 (0, 45; 0, 74)
0.58 (0.45, 0.74)

49, 7 74, 0 53, 5
22.2 12.7 22.6

butyronitryl (cas rn 109-74-0)
butyronitrile (cas rn 109-74-0)

70, 3 (52/ 74) 56, 6; 84, 0
70.3 (5 2/74) 56.6, 84.0

vat red. 1 (cas rn 2379-74-0)
vat red 1 (cas rn 2379-74-0)

≤ 0, 74 mbq strontu- 90 / 37 gbq itru- 90
≤ 0.74 mbq strontium-90 / 37 gbq yttrium-90

0, 49; 0, 74), stratyfikowany log- rank p < 0, 0001].
in an analysis adjusting for potential bias from unscheduled assessments, the rate of disease progression or death in patients who received vectibix was reduced by 40% relative to patients that received bsc [hazard ratio = 0.60, (95% ci 0.49, 0.74), stratified log-rank p < 0.0001].

74 ) zmienne 22 11 0 i 22 12 0 są przedstawiane co drugi rok .
variables 22 11 0 and 22 12 0 shall be reported every second year .

0, 69; 0, 81 0, 65; 0, 76 0, 64; 0, 75 0, 62; 0, 74 0, 63; 0, 75
0 56 0.75 0.70 0.23 0.34– 1.38 0.69, 0.81 6 53 0.71 0.69 0.20 0.34– 1.26 0.65, 0.76 12 50 0.70 0.68 0.19 0.36 – 1.18 0.64, 0.75 18 47 0.68 0.64 0.21 0.28– 1.38 0.62, 0.74 24 47 0.69 0.68 0.20 0.36– 1.32 0.63, 0.75

74 zgony w grupie leczonej atorwastatyną i 82 w grupie placebo, p=0, 51).
82 events, p=0.51).